 THE NATIONAL CANCER ITUTE OPENS A RANDOMIZED, DOUBLE-BLIND, PHASE 2 TRIAL OF GI-6301 YEAST-BRACHYURY VACCINE VERSUS PLACEBO IN COMBINATION WITH STANDARD OF CARE DEFINITIVE RADIOTHERAPY IN LOCALLY ADVANCED, UNRESECTABLE, CHORDOMA: 